Cellectis Plans Up to 70% Workforce Cut Amid Gene Therapy Pivot
NewsData.io · United States · Nov 15, 2026
Cellectis, a biotech firm with operations in New York and Raleigh, NC, plans to reduce its global workforce by up to 70%—potentially 160 of its 229 employees—as it exits cell therapy and pivots to in vivo gene editing. The cuts are expected to roll out through 2026 and 2027, pending completion of French works council consultation and compliance with both French and U.S. labor law. The company has also halted enrollment in its CAR-T clinical programs. Recruiters supporting life sciences clients should note the emerging candidate supply in biotech, particularly in gene therapy and clinical operations roles, as this reduction is part of a broader wave of biotech layoffs trending upward year over year.
Get the weekly brief by email
What changed in staffing last week, every Monday morning. Free. Unsubscribe anytime.
Related stories
Detroit ABC affiliate WXYZ-TV (Channel 7) has eliminated at least 30 positions through a combination of buyouts and layoffs, according to sources who…
Dole Packaged Foods will permanently close its Atwater, California processing facility and a nearby Livingston laboratory, eliminating 404 jobs in…
About 1,400 IRS IT employees displaced by DOGE-directed downsizing have been reorganized into 'ONE IRS Readiness' teams with no defined mission…
Lufthansa plans to eliminate 1,000 full-time positions at its flagship carrier, with reductions targeted at its Frankfurt and Munich hubs…